Medicare Just Rewired Breakthrough-Device Coverage — What RAPID Means for Diligence

← Back to All Insights

In the space of a few weeks this spring, CMS and the FDA rewired how a breakthrough medical device gets paid. The changes are still settling — the final piece is expected around August 1 — but the direction is already clear, and it quietly split the device world in two.

For anyone underwriting a medtech investment or acquisition, this is not a footnote. Reimbursement is the risk that most often survives a clean regulatory story and then kills the return. The rules governing it just moved.

What changed

Three moves, close together:

• RAPID (announced April 23, 2026). The Regulatory Alignment for Predictable and Immediate Device pathway aligns FDA and CMS earlier in development so that eligible breakthrough devices addressing an unmet need in a Medicare population can reach a national coverage decision within roughly 60–90 days of FDA authorization — with CMS issuing a proposed national coverage determination close to the moment of market authorization.
• The NTAP "alternative pathway" is proposed for repeal. Today, Breakthrough Devices can qualify for a new-technology add-on payment without separately demonstrating substantial clinical improvement. CMS has proposed ending that shortcut in the FY 2027 inpatient payment rule; if finalized, it would take effect in FY 2028.
• TCET is paused. CMS has stopped taking new candidates into the Transitional Coverage for Emerging Technologies pathway as it stands RAPID up.

Why it matters for diligence

Read the three moves together and reimbursement risk has bifurcated. A device that carries — or can realistically earn — FDA Breakthrough Device designation, and that addresses a Medicare-relevant unmet need, now has a fast, unusually predictable on-ramp to national coverage. That is a genuine value driver: it can pull real revenue forward by quarters, which is exactly what an investor is underwriting.

Everything else moved the other way. With TCET paused and the NTAP shortcut on its way out, a device without that designation faces the longer, evidence-heavy road — and now has to prove substantial clinical improvement to earn the add-on payment it might previously have received more easily. The gap between the two lanes is wider than it was a year ago.

"Is this device RAPID-eligible?" has moved from a footnote in the reimbursement section to a first-order question about time-to-revenue.

What to actually check

• Does the device hold FDA Breakthrough Device designation — or is there a credible, documented basis to expect it?
• Does it address an unmet need in a Medicare population, the frame RAPID is built around?
• Is there an evidence-generation plan that can support "substantial clinical improvement," now that the NTAP alternative pathway is going away?
• How does the coverage timeline change the model — RAPID's 60–90-day window versus the older multi-year slog — and has the raise or the deal case been re-run on the new assumptions rather than last year's?

None of this is a bet on any single coverage decision. It is a read on timeline and eligibility risk — which lane a company is in, how defensible that position is, and what it does to the revenue curve. That is the reimbursement question the RAPID era makes unavoidable.

At Vantage, the reimbursement domain of every assessment is grounded in current public CMS and FDA data and cited to it — including whether a target sits on the fast lane or the slow one under the new rules. As the FY 2027 final rule lands, we will keep this read current; nothing here is legal or regulatory advice.